Used in pharmaceutical research as an intermediate in the synthesis of dopamine receptor modulators. Its structure supports binding affinity to CNS targets, making it valuable in developing treatments for neurological disorders such as Parkinson’s disease and schizophrenia. The trifluoroacetamide group enhances metabolic stability, while the diethylindenyl moiety contributes to lipophilicity and blood-brain barrier penetration. Commonly employed in structure-activity relationship (SAR) studies to optimize potency and selectivity in dopaminergic compounds.